Books, Big Ideas, Q&As

A different ‘philosophy’ steers new drug pricing guidelines, says top PMPRB bureaucrat after contentious path to rule changes

Guideline changes became necessary after the Justin Trudeau government chose to amend the Patented Medicines Regulations, a process beset with legal challenges and many delays

Guillaume Couillard became director general of the Patented Medicine Prices Review Board in April 2023. He now leads a team that will monitor and review drug prices under new guidelines to enforce regulations that were put into force in July 2022. Photograph courtesy of the Patented Medicine Prices Review Board

News

BY TESSIE SANCI

July 20, 2025

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Podcast Newsletter

The people shaping politics and policy inside the bubble.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy